Connect with us
  • tg

Stock Markets

Pro Research: Wall Street dives into CRISPR Therapeutics’ gene editing future

letizo News

Published

on

Pro Research: Wall Street dives into CRISPR Therapeutics' gene editing future
© Reuters

Explore Wall Street’s expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This New Year, enjoy up to 50% off on a subscription to InvestingPro. In addition, take an extra 10% off a 2-year InvestingPro+ subscription with the code SFY24 or claim an extra 10% off a 1-year InvestingPro+ subscription with the code SFY241. To ensure ongoing access to valuable content like this, step up your investment game with InvestingPro.

The biotechnology sector is witnessing a paradigm shift as gene editing emerges as a transformative force in medicine. CRISPR Therapeutics AG (NASDAQ:CRSP), a frontrunner in this revolution, has recently garnered significant attention from Wall Street analysts. The company’s proprietary CRISPR/Cas9 platform has shown promise in developing gene-based therapies for serious diseases, including sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

Company Outlook and Market Performance

CRISPR Therapeutics has made headlines with the UK approval of its therapy CASGEVY for SCD/TDT patients, marking a significant milestone not only for the company but for the gene editing domain at large. The anticipated FDA approval in the US by early December 2023, with a high probability of 85%, could drive the stock’s upside by 15-25%. However, analysts note that revenue generation from CASGEVY will take time, with a profitable turn expected around 2028 based on physician surveys.

Product Pipeline and Clinical Trials

The company’s pipeline boasts promising therapies like CTX310 and CTX320 for cardiovascular diseases, with clinical trials expected to start in the first half of 2024. These therapies have demonstrated durability in reducing Lp(a) levels and show no off-target editing, aligning with regulatory safety concerns. Moreover, the company has a strong cash reserve, which supports ongoing trials and research into next-generation therapies like CTX112 (CD19) and CTX131 (CD70).

Competitive Landscape and Strategic Positioning

CRISPR Therapeutics faces a competitive landscape marked by rapid innovation and regulatory scrutiny. The company’s strategic focus on gene editing has positioned it well against its peers, with its therapies potentially offering one-time cures for diseases like SCD and TDT. Partnerships, such as with Vertex Pharmaceuticals (NASDAQ:), play a crucial role in the company’s strategy, providing milestones and support for its therapy launches.

Bear Case

Is CRISPR Therapeutics’ revenue growth sustainable?

Analysts express caution regarding the immediate commercial success of CRISPR Therapeutics’ gene-based therapies. The revenue generation from CASGEVY is not immediate and will require time to materialize, indicating that investors may need to be patient for the company’s financials to reflect its clinical successes.

What are the risks associated with CRISPR Therapeutics’ FDA approval process?

There are risks in the regulatory landscape, including the possibility of receiving a Complete Response Letter (CRL) from the FDA. Such an event carries a 15% probability and could lead to a 40-50% downside in CRSP’s stock price. The company’s therapies face scrutiny for safety concerns, with a particular focus on off-target editing risks.

Bull Case

What is the growth potential for CRISPR Therapeutics’ gene editing therapies?

Approval of CASGEVY in the UK and potential US approval could significantly improve investor sentiment. Analysts highlight the strong experience with payer interactions and physician willingness to prescribe CASGEVY, suggesting a significant future uptake. The company’s robust data from preclinical studies and its alignment with regulatory safety concerns bolster the bullish outlook.

How will CRISPR Therapeutics’ market presence evolve with upcoming product launches?

With multiple product launches on the horizon, CRISPR Therapeutics is poised to strengthen its market presence. The company’s diversified pipeline and partnerships provide significant optionality and growth prospects. The potential approval and commercialization of CTX001 by approximately 2024, along with the possible approval of allogeneic product CTX110 by around 2025, could validate the company’s platform and drive growth.

SWOT Analysis

Strengths:

– Pioneering gene editing platform with a focus on CRISPR/Cas9 technology.

– Strong pipeline with potential one-time cure therapies.

– Strategic partnerships enhancing product development and commercialization.

Weaknesses:

– Revenue generation from new therapies will require time.

– Regulatory risks associated with novel gene editing technologies.

– Market adoption may be slow due to treatment costs and infrastructure needs.

Opportunities:

– Expansion into new therapeutic areas and indications.

– Potential to set a new standard in treatments for genetic diseases.

– Growing market for gene editing therapies.

Threats:

– Competition from other biotechnology companies with similar platforms.

– Uncertainties in the regulatory environment.

– Intellectual property litigation risks.

Analysts Targets

– BMO Capital Markets: Outperform rating with a price target of $98.00 (November 17, 2023).

– RBC Capital Markets: Sector Perform rating with a price target of $57.00 (December 11, 2023).

– JMP Securities: Market Outperform rating with a price target of $80.00 (December 20, 2023).

– Barclays Capital Inc.: Equal Weight rating with a price target of $56.00 (November 7, 2023).

– Piper Sandler: Overweight rating with a price target of $105.00 (November 7, 2023).

The timeframe for the analysis spans from October to December 2023.

InvestingPro Insights

As CRISPR Therapeutics AG (NASDAQ:CRSP) continues to make strides in the biotech industry, real-time data and expert insights from InvestingPro paint a detailed picture of the company’s financial health and market performance. With a market capitalization of $6.56 billion and a significant revenue growth of over 1100% in the last twelve months as of Q3 2023, CRISPR Therapeutics is a standout in the sector. This remarkable revenue growth is a testament to the company’s innovative approach and the market’s response to its gene editing therapies.

InvestingPro Tips highlight that CRISPR Therapeutics holds more cash than debt on its balance sheet, providing financial stability and the ability to invest in future growth. Moreover, analysts anticipate sales growth in the current year, reflecting optimism about the company’s commercial prospects. These factors are crucial for investors considering the potential of CRISPR Therapeutics as it moves towards FDA approval and commercialization of its therapies.

Despite a negative P/E ratio of -17.94, indicating that the company is not currently profitable, CRISPR Therapeutics has seen a significant return over the last week, with a price total return of 10.74%. This suggests a positive market sentiment and investor confidence in the company’s trajectory. Additionally, the stock is trading near its 52-week high, at 94.56% of the peak price, further underscoring the bullish trend in its stock performance.

For investors seeking additional insights, there are 15 more InvestingPro Tips available for CRISPR Therapeutics at https://www.investing.com/pro/CRSP, providing a deeper dive into the company’s financials, market performance, and analyst expectations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Stock Markets

14 lessons from 2024 to remember in 2025: BofA

letizo News

Published

on

Investing.com — In a recent note, Bank of America outlined 14 key lessons from 2024 that investors should keep in mind as they head into 2025, warning that market momentum and stretched valuations could face headwinds in the year ahead.

While this year resembled the steady gains of 1996-97, rather than the bubble peaks of 1998-99, risks are mounting—from geopolitical tensions and rising debt to market fragility highlighted by the VIX.

BofA points to opportunities in Europe, China, and Japan but cautions that volatility, trade disputes, and macroeconomic uncertainty will shape the next leg of the market cycle.

Below are the 14 lessons that BofA highlighted.

1. 2024 was a strong year for markets, but it might only be the beginning.

2. The market’s performance in 2024 looked more like the steady gains of 1996-97 than the bubble peaks of 1998-99.

3. In a bubble environment, market leadership can persist for longer than investors can afford to stay underweight.

4. However, the combination of strong momentum and high valuations is already too stretched to avoid a potential bust.

5. The has shown that markets remain fragile, and a major shock may be overdue.

6. August 2024 suggests buying market dips and locking in volatility spikes; using smarter strategies like skewed delta positioning may be key for 2025.

7. Rising debt levels and persistent inflation mean bond vigilantes remain the most visible macroeconomic tail risk.

8. Market fragility, faster reactions, and elevated valuations suggest a repeat of the calm volatility seen in 2017 is unlikely.

9. A Trump election victory has reignited concerns around tariffs, with European companies favored by dollar strength potentially becoming the next trade targets.

10. European equities remain cheap and unloved—investors should be cautious about being caught short, as fewer crowded trades mean less volatility pain.

11. China’s outperformance over Japan in 2024 could continue if U.S. interest rates decline.

12. VIX options data indicates that positioning risks in the market have not gone away.

13. Eurozone bank dividends have outperformed the for much of the past year; investors may need to hedge against a different outcome in 2025.

14. The risk of sharp movements in the Japanese yen, driven by volatility, could cause instability for the in 2025.

Continue Reading

Stock Markets

Class Action Lawsuit Reminder WOLF: Kessler Topaz Meltzer & Check, LLP Reminds Wolfspeed, Inc. (WOLF) Investors – A Securities Fraud Class Action Lawsuit Has Been Filed

letizo News

Published

on

RADNOR, PA. – (NewMediaWire) – December 21, 2024 – The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Wolfspeed (NYSE:), Inc. (Wolfspeed) (NYSE: WOLF) on behalf of those who purchased or otherwise acquired Wolfspeed securities between August 16, 2023, and November 6, 2024, inclusive (the Class Period). The lead plaintiff deadline is January 17, 2025.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:

If you suffered Wolfspeed losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/wolfspeed-inc?utm_source=PR&utm_medium=link&utm_campaign=wolf&mktm=r

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at info@ktmc.com .

DEFENDANTS ALLEGED MISCONDUCT:

The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Wolfspeeds optimistic claims of potential growth of its Mohawk Valley fabrication facility and general demand for Wolfspeeds 200mm wafers in the electronic vehicle market fell short of reality; and (2) Wolfspeed had overstated demand for its key product and placed undue reliance on purported design wins while the Mohawk Valley facilitys growth had begun to taper before recognizing the $100 million revenue per quarter allegedly achievable with only 20% utilization of the fabrication, let alone the promised $2 billion revenue purportedly achievable by the facility.

Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/zMLfnSRjg2Y

THE LEAD PLAINTIFF PROCESS:

Wolfspeed investors may, no later than January 17, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Wolfspeed investors who have suffered significant losses to contact the firm directly to acquire more information.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaints in this action were not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com .

CONTACT:

Kessler Topaz Meltzer & Check, LLP

Jonathan Naji, Esq.

(484) 270-1453

280 King of Prussia Road

Radnor, PA 19087

info@ktmc.com

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

View the original release on www.newmediawire.com

Copyright 2024 JCN Newswire . All rights reserved.

Continue Reading

Stock Markets

Starbucks workers’ union strikes across US as talks hit impasse

letizo News

Published

on

By Savyata Mishra, Gursimran Mehar and Renee Hickman

(Reuters) -Some members of the Starbucks (NASDAQ:) workers’ union that represents more than 10,000 baristas walked off their jobs in multiple U.S. cities on Friday, citing unresolved issues over wages, staffing and schedules.

The five-day strike, which began on Friday and closed Starbucks cafes in Los Angeles, Chicago and Seattle, will expand to Columbus (WA:), Denver, and Pittsburgh through Saturday, the union said in a statement.

This is the latest in a series of labor actions that have picked up pace across service industries following a period when workers at manufacturers in the automotive, aerospace and rail industries won substantial concessions from employers.

At Starbucks, the Workers United union, which represents employees at 525 stores across the U.S., said late on Thursday that walkouts would escalate daily, and could reach “hundreds of stores” nationwide by Christmas Eve.

“It’s estimated that 10 stores out of 10,000 company-operated stores did not open today,” Starbucks said, adding that there was no significant impact to store operations on Friday.

Around 20 people joined a picket line at a Starbucks location on Chicago’s north side, buffeted by snow and wind, but cheering in response to the honking horns of passing cars.

A few confused customers tried to walk into the closed store before strikers began chanting, but union member Shep Searl said the reaction had been mostly positive.

Searl said 100% of the unionized workers at the Starbucks location in Chicago’s Edgewater neighborhood were participating in the strike, and according to the workers, they have been subject to numerous unfair labor practices including write-ups, “captive-audience” meetings and firings.

The union member said they made about $21 an hour and added, “that would have been a great wage in 2013”.

It is an inadequate wage, the baristas said, given inflation and the high cost of living in a large city, especially since they rarely get 40-hour work weeks.

WORKERS SNUB OFFER

Negotiations between the company and Workers United began in April, based on an established framework agreed upon in February, which could also help resolve numerous pending legal disputes.

The company said on Thursday it has held more than nine bargaining sessions with the union since April, and reached more than 30 agreements on “hundreds of topics”, including economic issues.

The Seattle-headquartered firm said it is ready to continue negotiations, claiming the union delegates prematurely ended the bargaining session this week.

The union, however, said in a Facebook (NASDAQ:) post on Friday that Starbucks had yet to present a serious economic proposal with less than two weeks remaining until the year-end contract deadline.

The workers’ group also snubbed an offer of no immediate wage hike and a guarantee of a 1.5% increase in future years.

“Workers United proposals call for an immediate increase in the minimum wage of hourly partners by 64%, and by 77% over the life of a three-year contract. This is not sustainable,” Starbucks said on Friday.

In response to Starbucks’ statement on the proposals, Michelle Eisen, a Starbucks barista and bargaining delegate, said, “Starbucks’ characterization of our proposals is misleading and they know it. We are ready to finalize a framework that includes new investments in baristas in the first year of contracts”.

Separately, the baristas’ union said on Friday that it filed a new labor practice charge against the coffee house, alleging Starbucks “refused to bargain and engaged in bad faith bargaining” over economic issues.

Hundreds of complaints have been filed with the National Labor Relations Board (NLRB), accusing Starbucks of unlawful labor practices such as firing union supporters and closing stores during labor campaigns. Starbucks has denied wrongdoing and said it respects the right of workers to choose whether to unionize.

WORKING ON A TURNAROUND

Last month, the NLRB said that Starbucks broke the law by telling workers at its flagship Seattle cafe that they would lose benefits if they joined a union.

“It’s (the strike) taking place during one of the busiest times of the year for Starbucks, which could magnify its impact while bringing unwanted public scrutiny into the company’s labor practices,” Emarketer analyst Rachel Wolff said.

The coffee chain is working on a turnaround under its newly appointed top boss, Brian Niccol, who aims to restore “coffee house culture” by overhauling cafes and simplifying its menu among other measures.

“Given how much Starbucks is already struggling to win over customers, it can ill afford any negative publicity – or impact to sales – that the strike could bring,” Wolff said.

© Reuters. Baristas picket in front of a Starbucks in Burbank, California, U.S., December 20, 2024. REUTERS/Daniel Cole

The Starbucks workers’ strike comes in the same week as Amazon.com (NASDAQ:) workers at seven U.S. facilities walking off the job on Thursday, during the holiday shopping rush.

There were 33 work stoppages in 2023, the most since 2000, though far lower than in past decades, data from the U.S. Bureau of Labor Statistics showed.

Continue Reading

Trending

©2021-2024 Letizo All Rights Reserved